Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/06/08 01:46:53」(JST)

wiki en

Ibandronic acid (INN) or ibandronate sodium (USAN) is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer.^[1] It may also be used to treat hypercalcemia (elevated blood calcium levels). Global sales in 2008 were 1.1B CHF ($1.0B USD at 01/01/2009 exchange rates).^[2]

Medical uses

Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women.^[3] In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.

Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.^[4]

Adverse effects

In 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint and/or muscle pain.^[5] A study conducted by the American Society of Bone and Mineral Research concluded that long term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. ^[6]

Brand names

Ibandronic acid is marketed under the trade names Boniva in the USA, Bondronat in Europe, Bonviva in Asia,Ibandrix in Ecuador and Bondrova in Pakistan.

References

^ Bauss F, Schimmer RC (March 2006). "Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis". Therapeutics and clinical risk management 2 (1): 3–18. PMC 1661644. PMID 18360577.
^ "Roche 2008 Annual Report" (PDF). Roche. Retrieved 2009-08-13.
^ "boniva". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
^ Sittig HB (2012). "Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate". Onkologie 35 (6): 380–7. doi:10.1159/000338947. PMID 22722461.
^ "Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)". U.S. Food and Drug Administration. Retrieved 27 October 2010.
^ "Drugs Commonly Prescribed for Osteoporosis Patients are Effective at Reducing Risk of Hip and Spine Fractures, But Panel Says May be Related to Unusual Thigh Bone Fractures When Used Long Term". Journal of Bone and Mineral Research=27 October 2010.

External links

Ibandronate bound to proteins in the PDB
Boniva Osteoporosis Treatment by GlaxoSmithKline and Roche Laboratories
Boniva adverse events reported to the FDA

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 慢性腎臓病患者における骨粗鬆症：診断、評価およびマネージメント osteoporosis in patients with chronic kidney disease diagnosis evaluation and management
2. 閉経後の女性における骨粗鬆症のマネージメントにおけるビスホスホネート bisphosphonates in the management of osteoporosis in postmenopausal women
3. 高カルシウム血症の治療 treatment of hypercalcemia
4. 多発性骨髄腫患者のビスフォスフォネート製剤の使用 the use of bisphosphonates in patients with multiple myeloma
5. 骨粗鬆症の予防 prevention of osteoporosis

English Journal

Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats.

Sakai S1, Takeda S2, Sugimoto M3, Shimizu M4, Shimonaka Y5, Yogo K6, Hashimoto J7, Bauss F8, Endo K9.
Bone.Bone.2015 Dec;81:449-58. doi: 10.1016/j.bone.2015.08.004. Epub 2015 Aug 15.
Bisphosphonates are widely used in the treatment of osteoporosis and contribute to the reduction of bone fractures. Ibandronate (IBN) is a highly potent, nitrogen-containing bisphosphonate, which is administered orally or intravenously at extended dosing intervals. Vitamin D or active vitamin D3 der
PMID 26281770

Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.

D'Amelio P1, Sassi F2, Buondonno I2, Fornelli G2, Spertino E2, D'Amico L3, Marchetti M2, Lucchiari M4, Roato I3, Isaia GC2.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.Osteoporos Int.2015 Dec;26(12):2785-91. doi: 10.1007/s00198-015-3189-8. Epub 2015 Jun 12.
We evaluated the effect of parathyroid hormone (PTH) on Wnt10b production by immune system cells in humans. We showed that bone anabolic effect of intermittent PTH treatment may be amplified by T cells through increased production of Wnt10b. Chronic increase in PTH as in primary hyperparathyroidism
PMID 26068297

Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.

Ito M1, Tobinai M2, Yoshida S2, Hashimoto J3, Nakamura T4.
Journal of bone and mineral metabolism.J Bone Miner Metab.2015 Nov 27. [Epub ahead of print]
We examined the efficacy of intravenous (IV) ibandronate 1 mg/month in patient subgroups in the phase III MOVER study. Here we present results of analyses on the incidence of fractures in patients with prevalent vertebral fractures (1 or ≥2, and ≥3) at screening and femoral neck (FN) bone min
PMID 26614597

Japanese Journal

Inflammatory Effects of Nitrogen-Containing Bisphosphonates (N-BPs): Modulation by Non-N-BPs

Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ 40(1), 25-33, 2017
NAID 130005188786

ビスホスホネートによる骨粗鬆症治療 (特集骨粗鬆症update : リハビリテーションとともに) -- (骨粗鬆症に対する薬物療法)

Monthly book medical rehabilitation (195), 47-52, 2016-04
NAID 40020855697

原発性骨粗鬆症に対する12カ月間のイバンドロネート注射製剤とエルデカルシトール併用治療の有効性と安全性の検討

日本骨粗鬆症学会雑誌 = The journal of Japan Osteoporosis Society 2(3), 275-283, 2016
NAID 40021039736

「イバンドロン酸」

Ibandronic acid
Systematic (IUPAC) name
	{1-Hydroxy-3-[methyl(pentyl)amino]propane-1,1-diyl}bis(phosphonic acid)
Clinical data
AHFS/Drugs.com	International Drug Names
Licence data	EMA:Link, US FDA:link
Pregnancy; category	US: C (Risk not ruled out);
Legal status	℞ (Prescription only);
Routes of; administration	Oral, intravenous
Pharmacokinetic data
Bioavailability	0.6%
Protein binding	90.9 to 99.5%; (concentration-dependent)
Metabolism	Nil
Half-life	10 to 60 hours
Excretion	Renal
Identifiers
CAS Registry Number	114084-78-5
ATC code	M05BA06
PubChem	CID: 60852
DrugBank	DB00710
ChemSpider	54839
UNII	UMD7G2653W
KEGG	D08056
ChEMBL	CHEMBL997
Chemical data
Formula	C9H23NO7P2
Molecular mass	319.229 g/mol
	SMILES O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O;
	InChI InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17) ; Key:MPBVHIBUJCELCL-UHFFFAOYSA-N ;
(what is this?) (verify)